Literature DB >> 12055112

Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study.

D Wetzel1, W Menke, R Dieter, V Smasal, B Giannetti, M Bulitta.   

Abstract

OBJECTIVES: To investigate the clinical efficacy and safety of escin-containing gels in the topical treatment of blunt impact injuries.
METHODS: Competitors in soccer, handball, or karate competitions were enrolled within two hours of sustaining a strain, sprain, or contusion and treated three times with the trial gel within a period of eight hours. Patients were randomised to three parallel groups consisting of two active treatment gels, containing escin (1% or 2%), 5% diethylammonium salicylate, and 5000 IU heparin, or placebo gel. Tenderness produced by pressure was measured at 0 (baseline), 1, 2, 3, 4, 6, and 24 hours after enrollment (within two hours of the injury). Tenderness was defined as the amount of pressure (measured by a calibrated caliper at the centre of the injury) that first produced a pain reaction as reported by the patient.
RESULTS: A total of 158 patients were enrolled; 156 were evaluated in the intention to treat analysis. The primary efficacy variable was the area under the curve for tenderness over a six hour period. The gel preparations containing 1% and 2% escin were significantly more effective (a priori ordered hypotheses testing controlling the multiple alpha = 5% significance level) than placebo (p(1) = 0.0001 and p(2) = 0.0002 respectively). The treatment effects were 5.7 kp h/cm(2) (95% confidence interval (CI) 2.9 to 8.5) and 5.9 kilopond (kp) h/cm(2) (95% CI 2.9 to 8.8) between 1% escin and placebo and between 2% escin and placebo respectively. These results were supported by secondary efficacy variables. The time to reach the baseline contralateral tenderness value (resolution of pain) at the injured site was shorter in the treatment groups than in the placebo group (p<0.0001). Both active gel preparations produced more rapid pain relief than the placebo gel. No relevant differences were detected between the two active gels. The safety and tolerability of the escin-containing gels were excellent.
CONCLUSIONS: Escin/diethylammonium salicylate/heparin combination gel preparations are effective and safe for the treatment of blunt impact injuries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055112      PMCID: PMC1724504          DOI: 10.1136/bjsm.36.3.183

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  16 in total

1.  [Tolerance for and efficacy of the gel 1328 AN in sports injuries].

Authors:  C Zuinen
Journal:  Rev Med Liege       Date:  1976-03-01

2.  Analysis of serial measurements in medical research.

Authors:  J N Matthews; D G Altman; M J Campbell; P Royston
Journal:  BMJ       Date:  1990-01-27

3.  [New findings on the efficacy and mode of action of the horse chestnut saponin escin].

Authors:  M Rothkopf; G Vogel
Journal:  Arzneimittelforschung       Date:  1976-02

4.  [Value of using Reparil-gel in sports traumatology].

Authors:  J M Crielaard; P Franchimont
Journal:  Acta Belg Med Phys       Date:  1986 Oct-Dec

5.  Effect of aescine on hypoxia-induced activation of human endothelial cells.

Authors:  T Arnould; D Janssens; C Michiels; J Remacle
Journal:  Eur J Pharmacol       Date:  1996-11-14       Impact factor: 4.432

6.  Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers.

Authors:  C Calabrese; P Preston
Journal:  Planta Med       Date:  1993-10       Impact factor: 3.352

Review 7.  Mechanisms of neutrophil-dependent and neutrophil-independent endothelial cell injury.

Authors:  J Varani; P A Ward
Journal:  Biol Signals       Date:  1994 Jan-Feb

8.  Inhibitory effect of locally administered heparin on leukocyte rolling and chemoattractant-induced firm adhesion in rat mesenteric venules in vivo.

Authors:  X Xie; H Thorlacius; J Raud; P Hedqvist; L Lindbom
Journal:  Br J Pharmacol       Date:  1997-11       Impact factor: 8.739

9.  Shear stress activates cytosolic phospholipase A2 (cPLA2) and MAP kinase in human endothelial cells.

Authors:  M J Pearce; T M McIntyre; S M Prescott; G A Zimmerman; R E Whatley
Journal:  Biochem Biophys Res Commun       Date:  1996-01-17       Impact factor: 3.575

10.  Treatment modalities for soft tissue injuries of the ankle: a critical review.

Authors:  D J Ogilvie-Harris; M Gilbart
Journal:  Clin J Sport Med       Date:  1995-07       Impact factor: 3.638

View more
  8 in total

1.  Diclofenac epolamine plus heparin plaster versus diclofenac epolamine plaster in mild to moderate ankle sprain: a randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase III trial.

Authors:  Cosimo Costantino; Jacek Kwarecki; Anatoly V Samokhin; Giuseppe Mautone; Stefano Rovati
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation.

Authors:  Ines Lindner; Christiane Meier; Angelika Url; Hermann Unger; Andreas Grassauer; Eva Prieschl-Grassauer; Petra Doerfler
Journal:  BMC Immunol       Date:  2010-05-21       Impact factor: 3.615

3.  Diclofenac patch for topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study.

Authors:  H G Predel; R Koll; H Pabst; R Dieter; G Gallacchi; B Giannetti; M Bulitta; J L Heidecker; E A Mueller
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

4.  Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway.

Authors:  Kuzhuvelil B Harikumar; Bokyung Sung; Manoj K Pandey; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Mol Pharmacol       Date:  2010-01-26       Impact factor: 4.436

5.  β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability.

Authors:  Elizabeth Harford-Wright; Nicolas Bidère; Julie Gavard
Journal:  Oncotarget       Date:  2016-10-11

Review 6.  Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties.

Authors:  Luca Gallelli
Journal:  Drug Des Devel Ther       Date:  2019-09-27       Impact factor: 4.162

7.  Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway.

Authors:  A Rimmon; A Vexler; L Berkovich; G Earon; I Ron; S Lev-Ari
Journal:  Biochem Res Int       Date:  2013-10-27

Review 8.  Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives.

Authors:  Tessa Moses; Kalliope K Papadopoulou; Anne Osbourn
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-10-06       Impact factor: 8.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.